TherapeuticsMD Inc (NASDAQ:TXMD) has been assigned a consensus rating of “Buy” from the twelve brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $14.75.
TXMD has been the topic of several analyst reports. ValuEngine cut TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Friday, June 1st. Cantor Fitzgerald set a $26.00 target price on TherapeuticsMD and gave the company a “buy” rating in a research report on Friday, August 10th. Oppenheimer set a $12.00 target price on TherapeuticsMD and gave the company a “buy” rating in a research report on Monday, July 30th. JPMorgan Chase & Co. assumed coverage on TherapeuticsMD in a research report on Friday, June 15th. They set an “overweight” rating and a $11.00 target price on the stock. Finally, Zacks Investment Research lowered TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, April 25th.
Shares of NASDAQ:TXMD opened at $5.49 on Wednesday. The company has a market cap of $1.21 billion, a P/E ratio of -14.84 and a beta of 1.53. The company has a debt-to-equity ratio of 0.94, a quick ratio of 7.79 and a current ratio of 7.88. TherapeuticsMD has a 12-month low of $4.34 and a 12-month high of $7.66.
A number of institutional investors have recently modified their holdings of the stock. Cetera Advisors LLC lifted its holdings in TherapeuticsMD by 18.1% during the first quarter. Cetera Advisors LLC now owns 57,450 shares of the company’s stock worth $281,000 after acquiring an additional 8,800 shares during the period. ING Groep NV lifted its holdings in TherapeuticsMD by 3.4% during the first quarter. ING Groep NV now owns 278,138 shares of the company’s stock worth $1,355,000 after acquiring an additional 9,176 shares during the period. Swiss National Bank lifted its holdings in TherapeuticsMD by 4.0% during the first quarter. Swiss National Bank now owns 301,400 shares of the company’s stock worth $1,468,000 after acquiring an additional 11,600 shares during the period. Iridian Asset Management LLC CT lifted its holdings in TherapeuticsMD by 20.3% during the second quarter. Iridian Asset Management LLC CT now owns 68,841 shares of the company’s stock worth $430,000 after acquiring an additional 11,629 shares during the period. Finally, OppenheimerFunds Inc. raised its stake in shares of TherapeuticsMD by 0.7% in the first quarter. OppenheimerFunds Inc. now owns 1,646,316 shares of the company’s stock valued at $8,017,000 after buying an additional 12,236 shares during the period. Institutional investors and hedge funds own 72.13% of the company’s stock.
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Further Reading: Market Capitalization – What it Means for Investors
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.